UCLA Researchers Design Process to Better Understand How Advanced Melanoma Adapts to Immunotherapy
Tuesday, May 9, 2017 - 11:31
in Health & Medicine
A new study by scientists at the UCLA Jonsson Comprehensive Cancer Center could be a significant step toward understanding how certain cases of advanced melanoma shield themselves from pembrolizumab, the FDA-approved treatment that harnesses the immune system to attack the disease.